ClinicalTrials.gg
RecruitingNCT01848028Updated Oct 27, 2026

PsoBest - The German Psoriasis Registry

An observational study in Psoriasis and Psoriatic-arthritis, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 109 studies in Arthritis, Psoriatic with a site in Germany — 10 open to participants now, 28 under way, 18 of them phase 3. Arthritis, Psoriatic · Germany.

Planned enrollment
2nd of 19
3,500 · median 500
Started
2008
the only one that year
Observational
19 of 109
4 open now
Primary completion
2032-12
later than 27 of 27 live
Registered
22nd of 109
by date

Among the 109 studies in Arthritis, Psoriatic with a site in Germany, this one is the 2nd largest by planned enrollment of the 19 observational ones that give a count, is the only one that started in 2008, is one of 19 observational ones, reaches primary completion later than 27 of the 27 other live ones, and was the 22nd registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

10 of the 109 studies in Arthritis, Psoriatic with a site in Germany are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Psoriatic with a site in Germany, or all of them as a file.
02

Study summary

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time. The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.

Read the detailed description

Background: Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time.

Objectives: Observation and analysis of the following outcomes of treatment with systemic antipsoriatics:

  1. Effectiveness in clinical practice ("real world")
  2. Benefits and needs on the patients' side
  3. Effectiveness in a long-term course over years
  4. Optimal maintenance dosages
  5. Safety and side-effects profile under routine conditions
  6. Use in case of and effect on co-morbidity
  7. Reliable predictors of response
  8. Benefit and effectiveness of possible combination therapies or alternating use of biologics and systemic therapies

Methods: The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.The registry started for seven treatment arms: Fumaric acid, methotrexate, ciclosporin A, efalizumab, etanercept, infliximab and adalimumab. While efalizumab was withdrawn from the market, ustekinumab was included after authorization. Patients are included at first initiation of a given treatment and will remain in the registry for 5 years, regardless of subsequent therapy. Nationwide, dermatologic practices and hospital ambulances with expertise in systemic and biologic treatment consecutively enrol patients. Follow-ups will be every 3 to 6 months, comprising patient and treatment characteristics, clinical parameters, patient-defined benefit, quality of life and adverse events. Standardized questionnaires will be addressed to the patient and to the dermatologist 12 times at the dermatologic centres. In interim intervals, patients are directly contacted another 9 times by mail. PsoBest is member of the ENCePP network of psoriasis-registries (www.psonet.eu).

03

Conditions studied

  • Psoriasis
  • Psoriatic-arthritis

Browse trials for

Keywords

  • patient registry
  • Germany
  • psoriasis
  • psoriatic-arthritis
  • biologics
  • Psonet
  • effectiveness
  • safety
  • biosimilars
04

In context

Arthritis, Psoriatic Reclassified

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

This study's planned enrollment of 3,500 is above the median of 280 across 244 observational studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with plaque-type psoriasis or psoriatic-arthritis starting the first systemic treatment with authorized atipsoriatic drugs in Germany.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist
  • age ≥ 18 years
  • being administered a specific systemic drug for the first time
  • to participate
  • sufficient language skills (German)

Exclusion criteria

Exclusion criteria:

  • lack of
  • patients being participants of clinical trials at the day of admission to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analysed separately)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,500 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Fumaric acid esters

    Intervention: Drug: conventional systemic: Fumaric acid esters, including Dimethylfumarate, all dosages, frequencies and durations prescribed

  • Methotrexate

    Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed

  • Cyclosporine A

    Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed

  • Efalizumab (withdrawn)

    Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed

  • Etanercept

    Intervention: Biological and biosimilars: Etanercept, all dosages, frequencies and durations prescribed

  • Infliximab

    Intervention: Biological and Biosimilars/-identicals: Infliximab, all dosages, frequencies and durations prescribed

  • Adalimumab

    Intervention: Biological and Biosimilars: Adalimumab, all dosages, frequencies and durations prescribed

  • Ustekinumab

    Intervention: Biological and Biosimilars: Ustekinumab, all dosages, frequencies and durations prescribed

  • Golimumab

    Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed

  • Secukinumab

    Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed

  • Apremilast

    Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed

  • Certolizumab

    Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed

  • Retinoids

    Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed

  • Leflunomids

    Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed

  • systemic PUVA

    Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed

  • Guselkumab

    Intervention: Biological: Guselkumab all dosages, frequencies and durations prescribed

  • Brodalumab

    Intervention: Biological: Brodalumab, all dosages, frequencies and durations prescribed

  • Tildrakizumab

    Intervention: Biological: Tildrakizumab, all dosages, frequencies and durations prescribed

  • Risankizumab

    Intervention: Biological: systemic Risankizumab, all dosages, frequencies and durations prescribed

  • Bimekizumab

    Intervention: Biological: Bimekizumab, all dosages, frequencies and durations prescribed

  • Tofacitinib

    Intervention: JAK-Inhibitor: Tofacitinib, all dosages, frequencies and durations prescribed

  • Upadacitinib

    Intervention: JAK-Inhibitor: Upadacitinib, all dosages, frequencies and durations prescribed

  • Deucravacitinib

    Intervention: JAK-Inhibitor: Deucravacitinib, all dosages, frequencies and durations prescribed

  • Ixekizumab

    Intervention: Biological: Ixekizumab, all dosages, frequencies and durations prescribed

  • No treatment

    Intervention: no systemic treatment in observation episodes

07

What researchers measure

Primary outcomes

  1. Psoriasis Area Severity Index (PASI)

    To evaluate clinical outcome of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 6 month for 10 years

Secondary outcomes

  1. Dermatology Life Quality Index (DLQI)

    To evaluate disease related quality of life of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 3 month for 10 years

Other outcomes

  1. Adverse and serious adverse events

    Risk for adverse events and serious adverse events for patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: 6 month

  2. Patient Benefit Index (PBI)

    To evaluate the patient benefit of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 3 months for 10 years

  3. EuroQol Questionnaire (EQ-5D)

    To evaluate general state of health of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 3 months for 10 years

  4. Questionnaire on Supply Quality in Dermatology (FVQ-d)

    To evaluate care characteristics of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 3 months for 10 years

  5. Health Assessment Questionnaire (HAQ)

    To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 6 months for 10 years

  6. Patient Global Assessment (Skin: PaGAs, Arthritis: PaGAa)

    To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 3 months for 10 years

  7. Physician Global Assessment (Skin: PGAs, Arthritis: PGAa)

    To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 6 months for 10 years

  8. Disease Activity Score 28 (DAS 28), American College of Rheumatology Score (ACR20), Psoriatic Arthritic Response Criteria (PsARC)

    To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis

    Time frame: every 6 months for 10 years

08

Study locations

1 of 1 sites recruiting
  • Nationwide group of dermatological centers, hospitals and medical offices
    Hamburg, Germany
    Recruiting
    • Matthias Augustin, Prof. Dr. · Contactm.augustin@uke.de
    • Matthias Augustin, Prof. Dr. · Principal investigator
09

References and documents

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2032 and a completion of Dec 2032. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2013
First posted
May 7, 2013
Start
Jan 2008
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2032
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Nationwide group of dermatological centers, hospitals and medical offices · Hamburg, GermanyContact person changed (no phone or email listed)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Nationwide group of dermatological centers, hospitals and medical offices · Hamburg, GermanyContact person changed (no phone or email listed)
    + 4 other changes: index terms, identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01848028
Collaborators
Berufsverband der Deutschen Dermatologen e.V. (www.bvdd.de), Deutsche Dermatologische Gesellschaft e.V. (https://derma.de), AbbVie, Biogen, Janssen-Cilag G.m.b.H, medac GmbH, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer Pharmaceuticals Ltd., Merck Serono GmbH, Germany, PsoNet.eu (http://www.psonet.eu/), Celgene, Eli Lilly and Company, Amgen, Almirall Hermal GmbH, UCB Pharma, Bristol-Myers Squibb, Viatris Inc., LEO Pharma
Responsible party
Sponsor
First posted
May 7, 2013
Start date
Jan 2008
Primary completion
Dec 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Oct 27, 2026

Study contacts

Matthias Augustin, Prof. Dr.
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion